Cimzia Injection, Solution
Product Images NDC 50474-750

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Cimzia (NDC 50474-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Cimzia 01)

Line chart comparing percentage of patients over 52 weeks for Placebo + MTX (n=199) and Cimzia 200 mg + MTX (n=393). The y-axis shows percentage of patients from 0 to 100%, and the x-axis represents weeks from 0 to 52. Cimzia + MTX shows a higher patient percentage over time compared to Placebo + MTX.*

FDA Label Image

Figure 2 (Cimzia 02)

A line graph comparing the percent responders over 24 weeks among three groups: placebo, Cimzia (certolizumab pegol) 200 mg every 2 weeks, and Cimzia 400 mg every 4 weeks. The x-axis shows time in weeks (0 to 24) and the y-axis shows percent responders (0% to 70%). Both Cimzia groups show higher response rates than placebo across all time points.*

FDA Label Image

Figure 3 (Cimzia 02a)

A line graph showing response rates (%) of patients over 24 weeks comparing Placebo, Cimzia 200 mg every two weeks, and Cimzia 400 mg every four weeks. The x-axis represents weeks, and the y-axis shows response rate percentage. Cimzia treatments show higher response rates than placebo throughout.*

FDA Label Image

Cimzia 02b

A line graph comparing the percentage of participants achieving an AS DAS-MI response over 12 weeks between Cimzia 200 mg given every two weeks and placebo groups. The x-axis represents weeks (0 to 12), and the y-axis shows the percentage with AS DAS-MI response (0 to 100%). Cimzia shows a progressive increase, significantly higher than placebo.*

FDA Label Image

Figure A And B (Cimzia 03)

Two labeled instructional diagrams related to an injection device. Figure A shows a close-up of the injection site and preparation steps including syringe components and biohazard container. Figure B details the parts of the syringe: plastic ring needle cap, needle, syringe barrel, finger grips, plunger rod, and plunger head.*

FDA Label Image

Figure C (Cimzia 04)

An instructional illustration labeled 'Figure C' depicting a Cimzia (certolizumab pegol) single-dose prefilled injection pen in its packaging. The image includes a magnified view highlighting the lot number and expiration date on the product label to guide proper identification before use.*

FDA Label Image

Figure D (Cimzia 05)

An instructional diagram showing recommended injection sites for subcutaneous administration on the front of the body. Highlighted areas include the abdomen, outer thighs, and upper arms. The diagram features a simplified outline of a human torso and legs with shaded regions indicating appropriate injection locations.*

FDA Label Image

Figure E (Cimzia 06)

An instructional illustration titled Figure E showing a hand removing the needle cap and plastic ring from a prefilled injection device. The image highlights the needle and plastic ring needle cap, indicating the step for preparing the device for subcutaneous injection.*

FDA Label Image

Figure F (Cimzia 07)

An instructional illustration labeled Figure F showing a person preparing to inject Cimzia (certolizumab pegol) subcutaneously. The image depicts the hand holding a syringe at a 45-degree angle to the abdomen, indicating the proper injection angle for subcutaneous administration.*

FDA Label Image

Figure G (Cimzia 08)

An instructional illustration labeled Figure G showing a hand holding a syringe with the plunger visible, positioned for injection into the skin.*

FDA Label Image

Figure H (Cimzia 09)

Instructional illustration labeled 'Figure H' depicting a hand holding an injection needle near the abdomen, with an arrow indicating a 45-degree angle for needle removal during subcutaneous injection.*

FDA Label Image

Figure I (Cimzia 10)

An instructional illustration labeled Figure 1 showing hands preparing a subcutaneous injection site using a cotton swab on the abdomen area.*

FDA Label Image

Figure J (Cimzia 11)

An instructional illustration labeled Figure J showing a hand holding a syringe above a sharps container. The container has a biohazard symbol and an opening for the safe disposal of needles or other sharp medical waste. The top right corner includes the text 'Sharps Container.'*

FDA Label Image

Figure 1 (Cimzia 12)

An instructional illustration showing two steps for using a Cimzia 200 mg/mL subcutaneous injection solution. The first step depicts a hand holding and removing a cap from a syringe. The second step shows the syringe being inserted into a vial, indicating medication preparation before injection.*

FDA Label Image

Figure 2 (Cimzia 13)

An instructional illustration showing two gloved hands holding a small vial or injection device, demonstrating a twisting or turning motion with curved arrows. This likely represents a step in preparing the Cimzia 200 mg/mL subcutaneous injection.*

FDA Label Image

Figure 3 (Cimzia 14)

An instructional illustration showing hands preparing a subcutaneous injection. One hand holds a syringe upright while the other hand removes the cap from the syringe needle, indicated by a downward arrow. This step is part of the injection preparation process for Cimzia (certolizumab pegol) 200 mg/mL solution.*

FDA Label Image

Figure 4 (Cimzia 15)

An instructional illustration showing a step in preparing a syringe for injection. The image depicts two hands holding a syringe, with an arrow indicating rotation or adjustment of the syringe plunger or needle cover. The number '4' in the corner suggests it is step 4 in a series of preparation instructions.*

FDA Label Image

Figure 5 (Cimzia 16)

Instructional illustration showing the step of injecting Cimzia (certolizumab pegol) subcutaneously into the abdomen area. The image depicts a person holding the injection device at the abdomen, demonstrating proper injection technique.*

FDA Label Image

Figure 6 (Cimzia 17)

An instructional illustration showing a person in underwear holding an injection device near the outer thigh, indicating the site for subcutaneous injection administration.*

FDA Label Image

Principal Display Panel (200 mg/vial carton)

Packaging label for Cimzia (certolizumab pegol) 200 mg/vial, a subcutaneous injection solution by UCB, Inc. The carton contains two vials, each with 200 mg certolizumab pegol, and includes components for reconstitution and administration. Storage instructions and customer support contact information are also provided on the label.*

FDA Label Image

Principal Display Panel (200 mg/mL Syringe Carton Box)

Cimzia (certolizumab pegol) Starter Kit carton label for subcutaneous injection, containing 3 cartons of 2 x 200 mg/mL prefilled syringes. The label includes dosing information and storage instructions to refrigerate at 2°C to 8°C. It features the labeler UCB, Inc. and mentions enrollment for CMplicity nursing support. The packaging displays syringe illustrations and emphasizes it is for Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.